All In Biotech

Free tool

FAERS Monitor: Amvuttra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215515 or its brand name (Amvuttra, Vutrisiran Sodium). Reports on generic versions are filed under their own applications.

Reports

2,969

Serious

2,505

84% of reports

Hospitalization

1,203

Death reported

745

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death601
  • hospitalisation367
  • intentional dose omission262
  • product dose omission issue168
  • fall142
  • fatigue122
  • dyspnoea104
  • cardiac failure94
  • therapy interrupted94
  • gait disturbance87
  • arthralgia80
  • asthenia80
  • pain in extremity76
  • ill-defined disorder75
  • atrial fibrillation74

Reports by year received

View as table
YearReports
20191
20211
202221
2023367
2024516
2025868
20261,195

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intentional dose omissionSignal26265.758.516,497
hospitalisationSignal36717.015.45,523
therapy interruptedSignal949.37.6692
ill-defined disorderSignal758.87.0508
cardiac failureSignal948.36.8598
atrial fibrillationSignal745.44.3261
deathSignal6014.94.61,967
product dose omission issueSignal1684.03.5388
gait disturbanceSignal873.22.6132
fallSignal1423.02.6193
pain in extremity761.81.528
asthenia801.51.213
arthralgia801.41.18
dyspnoea1041.31.17
fatigue1221.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.